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Abstract: Superparamagnetic iron oxide nanoparticles (SPIONs) bound directly to luteinizing 
hormone releasing hormone (LHRH) have shown high efﬁ  ciency for intracellular uptake to 
breast cancer cells, MDA-MB-435S.luc. We demonstrate in this communication that inclusion 
of a small spacer molecule such as glutaric acid (Glu) in between SPION and LHRH increases 
further receptor mediated intracellular uptake. LHRH-bound SPIONs with and without the 
spacer molecule were nontoxic. 
Keywords: Glutaric acid; luteinizing hormone releasing hormone; superparamagnetic iron 
oxide nanoparticles, MDA-MB-435S.luc., intracellular uptake 
Introduction
There is a growing interest in developing superparamagnetic nanoparticle-based 
materials that are biocompatible, biodegradable, and efﬁ  cient in intracellular uptake 
to cancer cells for applications in cancer therapy and diagnosis (Majumdar et al 
1989; Weissleder et al 1990; Josephson et al 1998; Huh et al 2005; Song et al 2005; 
Alexiou et al 2006; Zhou et al 2006). While there is a continuous progress in this 
direction in terms of excellent experimental and theoretical work, there are several 
challenges that need to be addressed (Soppimath et al 2001; Sapra and Allen 2003; 
Gabizon et al 2004; Matsumura et al 2004; Yoo and Park 2004). One of the most 
important challenges is to prevent uptake of nanoparticles by the reticuloendothelial 
system (RES) and enhance their circulation times so that they can navigate through 
irregularities of tumoral vasculature leading to efﬁ  cient intracellular uptake preferably 
via endocytosis. The efﬁ  cacy of a nanoparticulate system is determined by their abil-
ity for intracellular uptake in in vitro studies. Experimental studies, mathematical 
models, and computer simulations have already demonstrated that rapid intracellular 
uptake can be improved through suitable surface modiﬁ  cations, especially coating of 
superparamagnetic iron oxide nanoparticles (SPIONs) with hydrophilic polymers and 
surfactants (Jeon et al 1991; Lasic et al 1991; Torchlin et al 1994; Alexiou et al 2006). 
Several studies have demonstrated that polyethylene glycol (PEG) coatings, due to 
their biocompatibility, resistance to proteins, and lack of antigenicity, are the most 
widely utilized for increasing circulation times and enhancing intracellular uptake of 
SPIONs in cancer cells (Zhang and Zhang 2005). Dextran-coated SPIONs also have 
been demonstrated to improve intracellular uptake (Hogemann et al 2000; Berry et al 
2004; Funovics et al 2004). In addition to simple coatings such as PEG and dextran, 
there are also investigations related to more complex coatings involving multi-step 
synthetic procedures to prevent RES uptake and improved cellular uptake (Kohler et al 
2005, 2006; Neuberger et al 2005; Woo and Hong 2005; Koeseoglu 2006). However, 
to improve production and in vivo applications, it is important to avoid complicated 
and lengthy chemical procedures for SPION coatings. We recently demonstrated 
that ligands such as luteinizing hormone releasing hormone (LHRH) act as targeting International Journal of Nanomedicine 2007:2(2) 176
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agents for breast cancer cells that express receptors for LHRH 
(Leuschner et al 2003). We have also demonstrated that in-
tracellular accumulation of LHRH-bound SPIONs (without 
any PEG or dextran coating on SPIONs) in MDA-MB-435S.
luc cells in vitro was 12-fold higher than the corresponding 
free SPIONs uptake (Leuschner et al 2005, 2006; Zhou et 
al 2006). The results are not very surprising as LHRH is a 
decapeptide and can function as coating (in addition to being 
a targeting agent) thus preventing macrophage recognition, 
RES uptake, enhancing circulation time, and facilitating 
cellular uptake. 
In addition to demonstrating the concept of utilizing a 
targeting agent to act as a coating for improved intracellular 
uptake, we are also currently investigating the introduction 
of a small spacer between SPION and LHRH to engineer 
SPION conjugates for further improvements in intracellular 
uptake. In this study, we have synthesized SPIONs and 
covalently bound glutaric acid (Glu) to SPIONs followed 
by LHRH using carbodiimide chemistry. We present below 
details of synthesis, characterization, intracellular uptake, 
and cytotoxicity of newly engineered SPIONs and compare 
the data with that of free SPIONs and SPION–LHRH.
Experimental 
Iron II chloride (FeCl2.4H2O) 98%, iron III chloride (FeCl3) 
97%, ammonium hydroxide (NH4OH) 29.05%, 1-Ethyl-3-(3-
Dimethylaminopropyl)carbodiimide·hydrochloride (EDC), 
and Glu were purchased from Sigma Aldrich (St. Louis, 
MO, USA). Air-free nanopure water was made in the lab 
by reﬂ  uxing nanopure water, made with a Barnstead Nano-
Pure Water System (Barnstead International, Dubuque, IA, 
USA), under inert atmosphere. During the synthesis of the 
nanoparticles a 750D Sonicator (VWR International, Leuven, 
Belgium) was used, as well as a 1160A PolyScience Chiller 
(VWR International). 
The SPIONs used in this study were prepared using the 
procedure similar to the one reported by Kumar and colleagues 
(2004). For the covalent attachment of Glu to the SPIONs, 60 
mg of magnetite nanoparticles were dispersed 6 ml of water 
using a sonication bath at room temperature for ﬁ  fteen min-
utes. A solution of 42 mg carbodiimide and 1.5 ml water was 
added. The mixture was sonicated for 10 more minutes and 
then cooled to 4 °C in a chiller. A solution of 3.7 mg Glu in 
1.5 ml of water was added, and the reaction temperature was 
maintained at 4 °C for 2 h. The particles were then allowed to 
settle on a permanent magnet. The supernatant was removed 
and the particles were washed three times with water, twice 
with ethanol, and dried under nitrogen. 
The above procedure was followed for the function-
alization of the glutaric acid-bound SPIONs with LHRH. 
Substituting only 3.7 mg of LHRH instead of Glu and 60 
mg of Glu–SPIONs instead of plain magnetite.
The supernatant of the SPION–Glu particles and of 
the SPION–Glu–LHRH particles was analyzed by high-
performance liquid chromatography (HPLC) for the presence 
of unbound LHRH or Glu, according to which binding had 
taken place. The size and morphology of the magnetic nanopar-
ticles were observed using a JOEL 100X (JEOL Ltd.,1–2, 
Musashino 3-chome Akishima Tokyo, Japan) transmission 
electron microscopy (TEM) at 80kV. The mean diameter 
was estimated from 300 particles with the aid of MetaVue 
software (Molecular Devices Corporation, Downingtown, 
PA, USA). Binding of Glu and LHRH was conﬁ  rmed by 
Fourier transform infrared (FTIR) spectra obtained using a 
Thermo Nicolet Nexus 6/870 FTIR (Thermo Fisher Scientiﬁ  c, 
Inc., Waltham, MA, USA). Samples for FTIR analysis were 
R1=-CH2-CH2-COOH
R2=-CH2-CH2-CO-LHRH
R2-CO-NH
R1-CO-NH
NH-CO-R2
NH-CO-R2
NH-CO-R2
NH-CO-R1
NH2
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EDC
EDC
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NH2
NH2
NH2
NH2
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Figure 1 Schematic representation of step-wise binding of glutaric acid and LHRH to SPIONs.
Abbreviations: EDC, N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride; LHRH, luteinizing hormone releasing hormone; SPIONs, superparamagnetic iron 
oxide nanoparticles.International Journal of Nanomedicine 2007:2(2) 177
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prepared using KBr pellets. The magnetic properties of the 
SPION–Glu–LHRH particles were studied with a Quantum 
Design MPMS-5S SQUID magnetometer (Quantum Design, 
San Diego, CA, USA).
MDA-MB-435S human breast cancer cells were obtained 
from the American Type Culture Collection (Rockville, MD) 
and cultured as described previously (Leuschner et al 2003). 
MDA-MB-435S cells were transfected with exogenous DNA 
by lipofection using the plasmid pRC/CMV-luc containing 
the Photinus pyralis luciferase gene and an antibiotic resis-
tance gene under transcription control of the cytomegalovirus 
promoter (Rubio et al 1998, 2000). MDA-MB-435S.luc cells 
(60,000 cells/well) were grown in 24 well plates and incu-
bated with LHRH–SPION, LHRH–Glu–SPION or SPION 
(Fe 1 mg/ml) at 37 °C for 3 h in the presence and absence 
of LHRH (50 μM). At the end of the incubations the cells 
were detached from the culture plates, washed, centrifuged 
and the cell pellets were resuspended in HCl (1 M). Iron 
contents were determined spectrophotometrically using a 
Prussian Blue reaction kit. 
Toxicity studies were conducted in cultures of MDA-MB-
435S.luc cells using mitochondrial dependent formazan forma-
tion (MTT) assay as described by Berridge and Tan (1993). 
Results and discussion
The binding of LHRH and Glu to the SPION particles is 
facilitated by the presence of amine groups on the surface of 
the SPIONs (Kumar et al 2004; Shieh et al 2005). The syn-
thetic strategy adopted is shown in Figure 1. Analysis of the 
supernatant after the binding process by HPLC is one way to 
determine that binding has taken place. HPLC analysis did 
not reveal the presence of any free Glu or LHRH, conﬁ  rming 
that the biomolecules have been bound to the SPIONs. The 
size and morphology of SPION–Glu–LHRH nanoparticles 
0.5 µm 86303
Figure 2 A TEM micrograph of SPION–Glu–LHRH nanoparticles.
Abbreviations: Glu, glutaric acid; LHRH, luteinizing hormone releasing hormone; 
SPIONs, superparamagnetic iron oxide nanoparticles; TEM, transmission electron 
microscopy. 
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Figure 3 FTIR spectra of SPION, SPION–Glu, and SPION–Glu–LHRH.
Abbreviations: FTIR, Fourier transform infrared; Glu, glutaric acid; LHRH, luteinizing hormone releasing hormone; SPIONs, superparamagnetic iron oxide nanoparticles.International Journal of Nanomedicine 2007:2(2) 178
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Figure 4 Magnetic properties of LHRH-Glu-SPIONs. 
Abbreviations: Glu, glutaric acid; LHRH, luteinizing hormone releasing hormone; SPIONs, superparamagnetic iron oxide nanoparticles.
was investigated using TEM. A TEM micrograph of the 
nanoparticles is shown in Figure 2. The particles are roughly 
spherical in shape with a mean diameter of 9.12 nm. FTIR was 
also utilized to characterize SPION–Glu–LHRH nanoparticles. 
The particles exhibited typical amide bond signatures at around 
1652 cm–1 and the absence of carboxylic carbonyl stretching 
of glutaric acid at 1709 cm–1 (Figure 3). 
The SPION–Glu–LHRH nanoparticles are superpara-
magnetic as demonstrated by weak hysteresis in the plots 
of magnetization versus magnetic ﬁ  eld (M-H loop) at 10K 
(Figure 4). Compared with free SPIONs, SPION–Glu–LHRH 
nanoparticles showed lower saturation magnetization (Ms = 25 
Vs 72.1 emu/g). The reduction in Ms on binding Glu–LHRH 
to the SPIONS is not very surprising due to quenching of 
magnetic moment through electron exchange between organic 
molecules and surface atoms (Vanleeuwen et al 1994).
In vitro analysis of the potency for cellular uptake was 
carried out using breast cancer cells, MDA-MB-435S.luc 
that expresses LHRH-receptors. The results are shown in 
Figure 5. The results demonstrate that LHRH–SPION and 
LHRH–Glu–SPION speciﬁ  cally and more effectively accu-
mulate in the breast cancer cells, reaching 82.3 ± 25 pg/cell 
for SPIONs, 133 ± 17 pg/cell for Glu–SPIONs (p < 0.003 vs 
SPION), 165 ± 16 pg/cell for LHRH–SPIONs (p < 0.003 vs 
SPION) and 223 ± 16 pg/cell with LHRH–Glu–SPION (p < 
0.05 vs Glu–SPION, p < 0.002 vs LHRH–SPION). This accu-
mulation is signiﬁ  cantly reduced in the presence of the same 
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Figure 5 Intracellular uptake of LHRH–Glu–SPIONs.
Abbreviations: Glu, glutaric acid; LHRH, luteinizing hormone releasing hormone; 
SPIONs, superparamagnetic iron oxide nanoparticles.
ligand LHRH for LHRH–SPION and LHRH–Glu–SPION 
(106 ± 26 pg/cell, 123 ± 25 pg/cell, respectively, p < 0.001). 
This observation suggests that iron uptake was driven through 
receptor mediated endocytosis. The introduction of a spacer 
signiﬁ  cantly increased the intracellular iron uptake from 165 International Journal of Nanomedicine 2007:2(2) 179
LHRH-SPION with glutaric acid as a spacer
to 223.3 pg/cell, p < 0.001. Toxicity studies over a period of 
5 days revealed that none of the three iron oxide conjugates 
were toxic to human breast cancer cells (Figure 6). 
In summary, the work reported indicates that incorpora-
tion of a small spacer molecule such as Glu between LHRH 
and SPION shows signiﬁ  cant enhancement in intracellular 
uptake without causing toxicity to the breast cancer cells. 
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